解读功能格局和肺腺癌中增强子RNA的临床影响
Aike Li1, Liguang Zhang1, Xinsheng Du1
1Affiliated Hospital of Chengde Medical University, Chengde, 067000, Hebei, China.
Scientific reports
|August 12, 2025
概括
增强型RNAs (eRNAs) 在肺腺癌 (LUAD) 的发展中起着关键作用. 这些eRNA可以作为这种致命癌症的新型诊断生物标志物和治疗点.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 基因组学就是基因组学.
背景情况:
- 肺腺癌 (LUAD) 具有显著的死亡率和有限的治疗策略.
- 增强型RNAs (eRNAs) 越来越被认为是瘤发生的关键调节者,但它们在LUAD中的特定功能仍未得到充分探索.
研究的目的:
- 阐明 eRNAs 在 LUAD 发病过程中的作用.
- 评估eRNA作为诊断生物标志物和LUAD治疗点的潜力.
主要方法:
- 采用了综合生物信息学分析和实验验证.
- 不同表达分析确定了与LUAD相关的eRNAs.
- 建立以eRNA为中心的调控网络,包括与转录因子和RNA结合蛋白的相互作用.
主要成果:
- 鉴定了与LUAD进展相关的差异表达的eRNA,调节关键癌症途径.
- 发现了ERNA ENSR00000188682作为一个中央调节器,与特定的转录因子和ADRB2基因相互作用.
- 开发了一种使用 eRNA 表达形状具有显著诊断准确性的预测模型.
结论:
- eRNA是LUAD病原体的组成部分,影响细胞生长,免疫反应和瘤发育.
- eRNA ENSR00000188682及其监管网络代表了LUAD生物学中的重要发现.
- 作为预后生物标志物和治疗点,eRNA在改善LUAD患者的临床结果方面显示出巨大的前景.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K